OralModerate to severe vasomotor symptoms associated with menopauseAdult: Initially, 0.3 mg per day, cyclically (either 3 weeks on and 1 week off or 25 days on and 5 days off) or daily, depending on patient’s condition. Subsequent dosage adjustment may be made based on patient response. Use lowest effective dose for the shortest duration.
OralVaginal atrophy associated with menopause, Vulvar atrophy associated with menopauseAdult: Initially, 0.3 mg per day, cyclically (either 3 weeks on and 1 week off or 25 days on and 5 days off) or daily, depending on patient’s condition. Subsequent dosage adjustment may be made based on patient response. Use lowest effective dose for the shortest duration.
OralHypogonadism-associated estrogen deficiencyAdult: 0.3 or 0.625 mg per day given cyclically (either 3 weeks on and 1 week off or 25 days on and 5 days off). Dose may be titrated in 6-12-month intervals; add progestin treatment to maintain bone mineral density once skeletal maturity is achieved.
OralCastration-associated estrogen deficiency, Primary ovarian failure-associated estrogen deficiencyAdult: 1.25 mg per day given cyclically (either 3 weeks on and 1 week off or 25 days on and 5 days off). Dose may be adjusted based on patient response. Use lowest effective dose for the shortest duration.
OralProphylaxis of osteoporosis in postmenopausal womenAdult: Initially, 0.3 mg per day, cyclically (either 3 weeks on and 1 week off or 25 days on and 5 days off) or daily, depending on patient's condition. Subsequent dosage adjustment may be made based on patient response. Use lowest effective dose for the shortest duration.
ParenteralAbnormal uterine bleedingAdult: 25 mg via slow IV or IM inj, may repeat dose after 6-12 hours, if needed.
VaginalKraurosis vulvae associated with menopause, Menopausal atrophic vaginitisAdult: As 0.0625% cream: Initially, 0.5 g per day, given cyclically for 3 weeks of a 4-week cycle (21 days on, 7 days off). Adjust dose according to response (range: 0.5-2 g per day) Lowest effective dose should be used. Discontinue as promptly as possible.
VaginalModerate dyspareunia associated with menopause, Severe dyspareunia associated with menopauseAdult: 0.5 g twice weekly as a continuous regimen (e.g. Monday and Thursday) or once daily cyclically (21 days on, 7 days off).
|
|
|
Conjugated estrogens May be taken with or without food.
|
Incompatible with ascorbic acid, protein hydrolysate, or any solution with acidic pH.
|
Hypersensitivity. Undiagnosed abnormal bleeding, previous or current venous thromboembolism (e.g. DVT, pulmonary embolism); active or recent arterial thromboembolic disease (e.g. MI), suspected or history of breast cancer, known or suspected estrogen-dependent tumours, untreated endometrial hyperplasia, porphyria, thrombophilic disorders (e.g. protein C, protein S or antithrombin deficiency). Hepatic impairment. Pregnancy.
|
Patient with familial defects of lipoprotein metabolism, asthma, epilepsy, migraine, diabetes, porphyria, SLE, hereditary angioedema, hepatic haemangiomas, history of cholestatic jaundice associated with pregnancy or prior estrogen use; diseases that may be exacerbated by fluid retention (e.g. heart disease). Not intended for the prevention of CV disease or dementia. Renal impairment. Lactation.
|
Significant: Endometriosis, retinal vascular thrombosis, increased HDL and triglycerides, decreased LDL; increased risk of gallbladder disease.
Cardiac disorders: Vasodilation.
Eye disorders: Intolerance to contact lenses.
Gastrointestinal disorders: Nausea, flatulence, abdominal pain.
General disorders and administration site conditions: Oedema, weakness, pain.
Infections and infestations: Vaginitis, vaginal candidiasis.
Investigations: Changes in weight.
Musculoskeletal and connective tissue disorders: Arthralgias, leg cramps, back pain.
Nervous system disorders: Dizziness, headache, migraine, anxiety.
Psychiatric disorders: Depression, change in libido, mood disturbances, insomnia.
Reproductive system and breast disorders: Abnormal uterine bleeding, vaginitis, leucorrhoea, vaginal haemorrhage, breast pain, tenderness, enlargement, discharge.
Respiratory, thoracic and mediastinal disorders: Pharyngitis, sinusitis.
Skin and subcutaneous tissue disorders: Alopecia, melasma, hirsutism, pruritus, rash.
Vascular disorders: Venous thrombosis, pulmonary embolism.
Potentially Fatal: Anaphylaxis, angioedema; increased risk of endometrial cancer.
|
Assess for risk of breast cancer and CV disease prior to therapy. Monitor blood pressure, serum triglycerides, TSH (in patients taking thyroid replacement). Perform age appropriate breast and pelvic exams during therapy.
|
Symptoms: Abdominal pain, dizziness, drowsiness, nausea, vomiting, fatigue, breast tenderness, withdrawal bleeding. Management: Symptomatic treatment.
|
Decreased plasma concentrations with CYP3A4 inducers (e.g. phenytoin, rifampicin). Increased plasma concentrations with CYP3A4 inhibitors (e.g. erythromycin, ritonavir).
|
St. John’s wort may decrease estrogen plasma concentration.
|
Interfere with tests for coagulation factors, lipids, binding proteins, and glucose tolerance.
|
Description:
Mechanism of Action: Estrogens modulate pituitary secretion of gonadotropins, luteinising hormones and follicle-stimulating hormones through negative feedback mechanism, thus reducing elevated levels of these hormones in postmenopausal women during oestrogen replacement therapy
Pharmacokinetics:
Absorption: Well absorbed from the skin, mucous membranes, and gastrointestinal tract. Time to peak plasma concentration: 7 hours (total estrone).
Distribution: Widely distributed throughout the body with higher concentration in sex hormone target organs. Plasma protein binding: Binds to sex-hormone-binding globulin and albumin.
Metabolism: Metabolised in the liver by CYP3A4; undergoes enterohepatic recycling.
Excretion: Via urine (mainly as estriol, estradiol, estrone and conjugates). Elimination half-life: 27 hours (total estrone).
|
Tab/Vaginal cream: Store between 20-25°C. Solution for injection: Store at 2-8°C.
|
|
|
G03C - ESTROGENS ; Used in estrogenic hormone preparations.
|
Anon. Estrogens (Conjugated/Equine, Systemic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/01/2019. Anon. Estrogens (Conjugated/Equine, Topical). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/01/2019. Buckingham R (ed). Conjugated Oestrogens. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/01/2019. Premarin for Injection (Pfizer). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/01/2019. Premarin Tablet, Film Coated (Wyeth Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 10/01/2019. Premarin Vaginal Cream (Pfizer Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/01/2019. Premarin Vaginal Cream In A Nonliquefying Base (Wyeth). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/01/2019.
|
Sign Out
Continue with Google